Our five patient‐derived HRDhigh MFS and UPS cell models show sensitivity to both PARPi, with IC50 in a comparable range as the IC50 in BRCA1‐mutated ovarian carcinoma cells. Here, BRCA1 is linked to ovarian carcinoma.